



Fact Sheet

Neurology & Neuropsychiatry





SCOPE is a full-service, global CRO with a proven track record in managing all major indications across clinical phases I–IV, including paediatric trials, orphan drugs, medical devices, non-interventional studies (NIS), and post-authorization studies. Leveraging close relationships with leading investigators and key opinion leaders worldwide, SCOPE delivers high-quality solutions on time and on budget.

Despite advances in understanding central nervous system (CNS) diseases, healthcare systems face unprecedented challenges addressing unmet needs in neurological disorders. CNS conditions, particularly mental health disorders, are among the major health challenges of the 21st century, intensified by an aging population.



30 / Completed CNS Studies

1,200 / Qualified Sites

7,000 / Subjects



Patient-Centric Approach & Endpoint Reliability

CNS trials often rely on subjective endpoints, making the choice of psychometric instruments critical to demonstrate efficacy. SCOPE advises on guideline-conforming, well-defined tools, supports rater training, and ensures standardisation, so data are consistent and evaluable across sites. To reduce patient burden, we implement technology-driven data collection, including:

- Handheld devices and tablets
- Smartphone apps
- Electronic Patient Reported Outcome (e-PRO) instruments
- Collaboration with selected eCOA providers
- Training for study coordinators and patients to ensure timely and accurate data capture

Your CRO of Choice for CNS



CNS Expertise & Study Support

SCOPE's CNS / neurology team helps your clinical development programme succeed with innovative recruitment strategies, strong site networks, and local standard-of-care knowledge across a variety of neurological conditions. Our dedicated CNS project managers combine best practices with up-to-date knowledge of neurological and psychiatric rating instruments, underpinned by strong local and global regulatory insight.

We offer a full range of services, from defining a strong development plan for your drug, device, or combination product to overseeing the study from concept to final

report. Our established networks of neurologists, psychiatrists, pain/palliative specialists, and key opinion leaders allow rapid and accurate feasibility estimates, helping sponsors plan and execute studies efficiently.

We build upon long-term relationships with experienced, qualified, and motivated sites to ensure successful trial delivery. From identifying the best sites and recruiting the right patients to ensuring assessments are completed by trained personnel, SCOPE meets the challenges of hard-to-recruit indications and complex CNS study designs.

Additional study support includes:

- Standardisation and rater training for psychometric instruments
- Continuous site training, assessment, and feedback
- Identification and mitigation of study risks



Therapeutic Areas

Epilepsy (including paediatrics)

Parkinson's Disease

Bipolar Disorder

Mania & Depression

Alzheimer's Disease

Sensorineural Disorder

Multiple Sclerosis

Narcolepsy

PROVEN RESULTS IN
CNS



“Expertise where precision matters most”

SCOPE demonstrated strong expertise in CNS study design, rater training, and site management, ensuring consistent and evaluable data across sites.

Clinical Operations Director, Pharmaceutical Company

SCOPE International AG
Konrad-Zuse-Ring 18
68163 Mannheim, Germany
Phone +49 621 42939 0

For further information please contact
SCOPE's Business Development Team:
contact@scope-international.com